Kenya has become the first East African country to receive Lenacapavir, a long-acting Pre-Exposure Prophylaxis (PrEP) drug that protects HIV-negative people from contracting the virus. This is a major step forward in the fight against HIV. The drug only needs to be administered twice a year, making it easier and more convenient for people at risk.
The first batch arrived on Tuesday night, marking an important milestone in Kenya’s HIV prevention efforts. Being the first country in East Africa to receive this medicine shows Kenya’s commitment to protecting its people and reducing new HIV infections.
In my opinion, this is a big achievement for the nation. HIV has affected many families for years, and prevention is always better than treatment. A long-acting drug like Lenacapavir can help many people stay protected without the challenge of taking daily pills.
However, the success of this initiative will depend on proper distribution, awareness, and fighting stigma. People must feel safe and supported when accessing HIV prevention services. The government and health organisations should ensure that the drug reaches those who need it most, especially young people and vulnerable groups.
This milestone brings hope. It is not just about receiving medicine; it is about protecting lives and building a healthier future for Kenya.
